Pharma - Q1FY24 - Earnings Preview
The Pharma companies under our coverage are likely to report aggregate Revenue/ EBITDA/PAT growth of 22.1%/50.4%/39.5% YoY in Q1FY24E.
219 Views
Pick of the Week: Lupin Ltd - 10 JULY 2023
Lupin is an innovation-led transnational pharmaceutical company. It, develops and commercializes a wide range of branded and generic formulations,...
252 Views
Lupin - GSpiriva Approval a Overall Turnaround in The Business
Lupin has received approval from generic version of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) from USFDA in the US Market.
276 Views
LUPIN Ltd - Margins Improvement to Be The Key to Future Performance
US sales got impacted due to the lack of new launches and seasonality, gSupreb has strong volume growth, and Alubetrol has a stable market share of...
355 Views
LUPIN Ltd - Margins Still Below Industry Levels
The US sales stood at $177 Mn (+11% YoY) and the growth was supported by flu season, and new launches such as gSuprep, gPerforomist, Pennsaid, and...
224 Views